Out of stock
ব্যবসার জন্য পাইকারি দামে পণ্য কিনতে রেজিস্টেশন করুন
Register
0 People recently viewed this
Certican 0.25
Nevian Lifescience PLC
Generic: Everolimus
Safety Advices
বাংলা
English
CONSULT YOUR DOCTOR
It is not known whether it is safe to consume alcohol with Certican 0.25. Please consult your doctor.
CONSULT YOUR DOCTOR
Certican 0.25 is unsafe to use during pregnancy as there is definite evidence of risk to the developing baby. However, the doctor may rarely prescribe it in some life-threatening situations if the benefits are more than the potential risks. Please consult your doctor.
CONSULT YOUR DOCTOR
Certican 0.25 is probably unsafe to use during breastfeeding. Limited human data suggests that the drug may pass into the breastmilk and harm the baby.
UNSAFE
Certican 0.25 may cause side effects which could affect your ability to drive.
As fatigue is a common side effect with Certican 0.25 and this may affect your ability to drive
SAFE IF PRESCRIBED
Certican 0.25 is safe to use in patients with kidney disease. No dose adjustment of Certican 0.25 is recommended.
CAUTION
Certican 0.25 should be used with caution in patients with liver disease. Dose adjustment of Certican 0.25 may be needed. Please consult your doctor.
Use of Certican 0.25 is not recommended in patients with severe liver disease.
Medicine Overview of Certican 0.25 0.25mg Tablet
Introduction
Certican 0.25 is used for the prevention of organ rejection in transplant patients. It regulates the body’s immune response, so the body can accept the new organ. It is also used in combination with other medicines to treat cancers of breast, pancreas, lungs and kidney. Certican 0.25 must be taken in a dose and duration as per the prescription. It can be taken with or without food but make sure to take it at about the same time every day. An overdose of this medicine may have serious side effects on the body. The common side effects of this medicine...
... Show moreUses of Certican 0.25
- Breast cancer
- Pancreatic cancer
- Lung cancer
- Kidney cancer
Side effects of Certican 0.25
Common
- Weakness
- Sinus inflammation
- Infection
- Fever
- Cough
- Fatigue
- Stomatitis (Inflammation of the mouth)
- Otitis media (infection of ear)
- Diarrhea
- Upper respiratory tract infection
How to use Certican 0.25
Take this medicine in the dose and duration as advised by your doctor. Swallow it as a whole. Do not chew, crush or break it. Certican 0.25 may be taken with or without food, but it is better to take it at a fixed time.
How Certican 0.25 works
Certican 0.25 suppresses the activity of body's immune system and prevents rejection of the transplanted organ.
Quick Tips
- Do not start everolimus and consult your doctor if you have liver problems, diabetes, high blood cholesterol, had a recent surgery or have unhealed wound after surgery, have infection, previously had hepatitis, are pregnant or breast-feeding or have intolerance to some sugars.
- Seek medical advice if you have increased thirst or increased frequency of urination, if you get any infection, suffer from shortness of breath, cough or fever, need to receive any vaccination after taking everolimus.
- Everolimus may affect male or female fertility; consult your doctor if you are planning to have a child.
- Do not drive or operate machinery while taking everolimus as it may cause fatigue.
Brief Description
Indication
Breast cancer, Kidney cancer, Renal transplant, Liver transplant, Neuroendocrine tumors, Renal cell carcinoma, Astrocytoma, Renal angiomyolipoma,Tuberous sclerosis
Administration
May be taken with or without food. Administer consistently with food or consistently without food.
Adult Dose
Oral
Breast Cancer, Renal Cell Carcinoma, Renal Angiomyolipomas with TSC, Advanced Neuroendocrine Tumors
10 mg once daily with or without food
Contraindication
Patients with hypersensitivity to the active substance, to other rapamycin derivatives, or to any of the excipients. Hypersensitivity reactions manifested by symptoms including, but not limited to, anaphylaxis, dyspnea, flushing, chest pain, or angioedema (e.g., swelling of the airways or tongue, with or without respiratory impairment) have been observed with everolimus and other rapamycin derivatives
Mode of Action
Everolimus, a proliferation signal inhibitor, prevents allograft rejection in rodent and nonhuman primate models of allotransplantation. It exerts its immunosuppressive effect by inhibiting the proliferation and thus, clonal expansion, of antigen-activated T cells which is driven by T cell-specific interleukins eg, interleukin-2 and interleukin-15. Everolimus inhibits an intracellular signaling pathway that normally leads to cell proliferation when triggered by the binding of these T cell growth factors to their receptors. The blockage of this signal by everolimus causes cells to be arrested at the G1 stage of the cell cycle. At the molecular level, everolimus forms a complex with the...
... Show morePrecaution
Patients taking concomitant ACE inhibitor therapy may be at increased risk for angioedema Interstitial lung disease/noninfectious pneumonitis; monitor for clinical symptoms or radiological changes; fatal cases have occurred; manage by dose reduction or discontinuation until symptoms resolve, and consider use of corticosteroids; pulmonary hypertension (including pulmonary arterial hypertension) as a secondary event reported Elicits immunosuppressive effects and may increase risk for infections; some infections have been severe or fatal; monitor for signs and symptoms and treat promptly Pneumocystis jiroveci pneumonia, some with a fatal outcome, reported; this may be associated with concomitant use of corticosteroids or other immunosuppressive agents Mouth...
... Show moreSide Effect
>10%
Stomatitis (44%),Constipation (38%),Infections (37%),Asthenia (33%),Fatigue (31%),Cough (30%),Diarrhea (30%),Rash (29%),Anemia (26%),Nausea (26%),Anorexia (25%),Edema, peripheral (25-45%),Dyspnea (24%),Pyrexia (20%),Vomiting (20%),Headache (19%),Epistaxis (18%),Decreased lymphocytes, Grade 3 (16%),Increased glucose, Grade 3 (15%),Pneumonitis (14%),Pruritus (14%),Dry skin (13%),Decreased Hgb, Grade 3 (12%),Menstrual irregularities (11%)
1-10% (selected)
Dysgeusia (10%),Hypertension (4%),Hemorrhage (3%),Tachycardia (3%),CHF (1%)
Pregnancy Category Note
Pregnancy Based on animal studies and mechanism of action therapy can cause fetal harm when administered to pregnant woman; there are limited case reports of use in pregnant women; however, these reports are not sufficient to inform about risks of birth defects or miscarriage; advise pregnant women of potential risk to fetus Contraception Females Advise female patients of reproductive potential to use effective contraception during treatment and for 8 weeks after last dose Verify the pregnancy status of females of reproductive potential prior to starting treatment Males Based on findings in animal reproduction studies, advise male patients with female partners...
... Show moreInteraction
CYP3A4 inhibitors &/or inducers, CYP2D6 substrates w/ narrow therapeutic index, PgP inhibitors, rifampicin, ACE inhibitors, grapefruit juice & live vaccines.
ব্যবসার জন্য পাইকারি দামে পণ্য কিনতে রেজিস্টেশন করুন
Register